
Opinion|Videos|March 11, 2025
Optimizing Treatment Sequencing in Advanced Colorectal Cancer
Experts discuss additional factors considered when determining the most effective sequence of therapies for metastatic colorectal cancer, including fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab, and explore the further research needed to understand optimal sequencing of these treatments better.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What additional factors do you consider when determining the most effective sequence of these therapies (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab)?
- What further research is needed to understand optimal sequencing of these therapies better?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Long-Term Remission in Ph-Negative B-ALL With Sequential CAR T, ASCT
4
5 Ways ACOs Can Improve Care, Achieve Meaningful Savings
5












































